查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1993913

癌症生技药品市场：按药物、应用、作用机制、最终用户、国家和地区划分－全球产业分析、市场规模、市场份额和预测（2026-2033 年）

Cancer Biologics Market, By Drug, By Application, By Mechanism, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 382 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025年癌症生技药品市场价值526.1068亿美元，预计从2026年到2033年将以8.71%的复合年增长率成长。

癌症生技药品是一类创新药物，由蛋白质、抗体和细胞等天然物质製成，旨在预防、治疗或控制癌症。与影响体内正常细胞和癌细胞的传统治疗方法不同，癌症生物製剂针对特定的癌细胞。代表性药物包括单株抗体、癌症疫苗和重组蛋白。它们的作用机转包括活化人体免疫系统、阻断肿瘤生长讯号或直接攻击癌细胞。与传统治疗方法相比，癌症生技药品通常具有副作用较少的治疗优势。

大约五分之一的人一生中会罹患癌症，随着人口成长和老化，预计未来几年全球新患者数将持续增加。在全球医疗保健领域，癌症负担持续显着加重，推动了对先进治疗方案的需求，而癌症治疗市场正是在此背景下蓬勃发展的。根据世界卫生组织及其下属癌症研究机构－国际癌症研究机构（IARC）统计，2022年全球报告新增癌症病例约2000万例，癌症相关死亡病例约970万例，凸显了癌症对全球健康的重大威胁。因此，各国政府和公共卫生机构正在引进包括生物製药在内的创新治疗方法，作为更广泛的癌症防治策略的一部分，以提高治疗的精准性和临床疗效。

癌症生技药品市场—市场动态

核准并投入临床应用的生物製药疗法数量增加

主要医疗市场的监管机构正陆续核准生物製药疗法，加速其融入现代癌症治疗通讯协定。随着法律规范的完善，患者能够及时获得先进药物，医疗服务提供者也越来越多地将生物製药纳入癌症治疗。例如，根据美国食品药物管理局（FDA）的数据显示，其药物评估与研究中心在2023年核准了55种新药，肿瘤学仍然是生物製药和标靶治疗最活跃的治疗领域之一。在此趋势下，默克和百时美施贵宝等製药公司正稳步拓展其在肿瘤领域的生物製药研发管线，包括Keytruda和Opdivo等免疫疗法，这显示医学界对生物製药癌症治疗的接受度日益提高。总而言之，生物製药製剂监管核准数量的增加和临床应用的不断拓展正在推动癌症治疗的进步，改善患者获得创新疗法的机会，并刺激对先进癌症疗法研发的持续投资。

癌症生技药品市场－市场区隔分析：

全球癌症生技药品市场按药物、应用、作用机制、最终用户和地区进行细分。

在三种作用机制中，标靶免疫调节预计将在市场中发挥核心作用。这主要是由于免疫疗法的应用日益广泛，这类疗法能够增强人体免疫系统，使其更有效地识别和攻击癌细胞。免疫查核点抑制剂等治疗方法已在多种癌症类型中展现出显着的临床疗效，包括肺癌、恶性黑色素瘤和肾癌。政府和监管数据表明，基于免疫系统的生物製药的作用正在扩大。根据一项国际监管调查，主要市场已核准超过80种免疫查核点抑制剂的临床适应症，涵盖约20种癌症类型，其中许多被核准为第一线疗法或联合治疗。此外，根据癌症研究所（CRI）发布的一项分析，2011年至2024年间，全球已核准超过120种免疫疗法，其中免疫查核点抑制剂占已核准癌症免疫疗法的最大份额。因此，标靶免疫调节疗法因其能够为多种癌症带来持续疗效并提高存活率，在临床实践中仍备受重视。

从药物类型来看，单株抗体预计将在癌症生技药品市场中显着成长。这类药物广泛应用于肿瘤治疗领域，因为它们能够精准靶向癌细胞上的特定蛋白，从而在增强治疗效果的同时，最大限度地减少对健康组织的损伤。这些生技药品广泛应用于多种癌症类型，包括乳癌、肺癌和大肠癌，这推动了其在全球的临床应用不断扩大。 2024年FDA生物製药核准情况的分析显示，共有13种单株抗体获得监管部门核准，其中包括一些用于肿瘤治疗的药物，反映了抗体类生物製药的持续创新和监管重点。例如，默克的免疫疗法药物Keytruda预计在2024年将创造约294.8亿美元的全球整体销售额，使其成为全球领先的抗癌生物製药之一。

癌症生技药品市场—区域洞察

从区域来看，癌症生技药品市场在医疗基础设施、研究能力和治疗方法可近性方面存在显着的区域差异。北美地区凭藉其先进的医疗基础设施、政府大力支持的研究项目以及完善的主导法规环境（有利于创新生物癌症治疗方法的开发和核准），预计将继续保持其在癌症生技药品市场的领先地位。此外，该地区许多大型生物技术和製药公司的存在，以及广泛的临床研究活动，持续推动生物製药製剂在癌症治疗领域的应用。一些政府数据进一步凸显了该地区对癌症治疗的强劲临床需求。根据美国癌症协会统计，2022年全球整体新增癌症病例约2000万例，死亡病例约970万例，凸显了全球癌症负担的日益加重以及对生物製剂等先进治疗方法的迫切需求。

在北美，美国凭藉其庞大的患者群体和强大的生物医学研究生态系统，成为区域市场的主要贡献者。根据美国疾病管制与预防中心（CDC）的美国癌症统计项目，2022年美国报告了1,851,238例新增癌症病例，预计2023年将有613,349例癌症相关死亡病例，这清楚地表明了对先进癌症治疗方案的巨大需求。总体而言，严重的癌症负担、政府的支持、先进的医疗保健体係以及强大的研发投入正在推动癌症生技药品市场的发展。

印度癌症生技药品市场—各国概况

在癌症负担日益加重、医疗基础设施不断完善以及对生物技术创新的日益重视的推动下，印度正逐步崛起为癌症生技药品的重要市场。根据印度医学研究理事会（ICMR）国家癌症登记计画（NCRP）的数据，2022年印度报告了约146万例新增癌症病例，预计到2025年这一数字将达到约157万例。这表明对生物製药疗法等先进治疗方法的需求日益增长。多项政府措施也正在加强该国的癌症诊疗水准。例如，印度卫生和家庭福利部正在实施国家癌症、糖尿病、心血管疾病和中风预防与管理计划（NPCDCS），该计划致力于改善各邦的癌症筛检、诊断和治疗基础设施。日益加重的癌症负担、政府的医疗支持以及本土生物製药公司不断涌入市场，这些因素共同作用，正在巩固印度在癌症生技药品领域的地位。对生物技术研发的持续投入和生物相似药生产的扩大有望改善获得先进癌症治疗的机会，并促进该国生物製药市场的逐步发展。

目录

第一章：生技药品市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：生技药品市场的主要趋势

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 未来市场趋势

第四章：生技药品产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长前景展望图
  • 管理体制分析

第五章：生技药品市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：生技药品市场趋势

  • 癌症生技药品市场占有率分析，2025年
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章 癌症生技药品市场：依药物类型划分

  • 概述
    • 细分市场占有率分析：依药物划分
    • 单株抗体
    • 细胞疗法
    • 重组蛋白和细胞激素
    • 癌症疫苗
    • 溶瘤病毒

第八章 癌症生技药品市场：依应用领域划分

  • 概述
    • 细分市场占有率分析：按应用
    • 血癌
    • 乳癌
    • 肺癌
    • 大肠直肠癌和其他固体癌

第九章：癌症生技药品市场：依作用机制划分

  • 概述
    • 细分市场占有率分析：依作用机制划分
    • 标靶免疫调节
    • 肿瘤特异性细胞疗法
    • 血管生成和生长因子抑制剂
    • 其他的

第十章 癌症生技药品市场：依最终用户划分

  • 概述
    • 细分市场占有率分析：依最终用户划分
    • 医院
    • 诊所
    • 研究机构
    • 其他的

第十一章生技药品市场：依地区划分

  • 介绍
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 主要製造商：欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 概述
    • 主要製造商：亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他亚太国家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他拉丁美洲国家
  • 中东和非洲
    • 概述
    • 主要生产商：中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他中东和非洲国家

第十二章：主要供应商分析：癌症生技药品产业

  • 竞争基准
    • 竞争对手仪錶板
    • 竞争定位
  • 公司简介
    • F. Hoffmann La Roche Ltd
    • Novartis AG
    • Merck & Co.
    • Bristol Myers Squibb
    • Johnson & Johnson
    • Eli Lilly and Company
    • Sanofi
    • AbbVie Inc.
    • Amgen Inc.
    • BioNTech
    • Genmab
    • Incyte Corporation
    • Roche
    • Bayer
    • Others

第十三章：分析师的综合视角

简介目录
Product Code: ANV6124

Cancer Biologics Market size was valued at US$ 52,610.68 Million in 2025, expanding at a CAGR of 8.71% from 2026 to 2033.

Cancer biologics are an innovative class of medicines derived from living organisms such as proteins, antibodies, or cells, designed to prevent, treat, or manage cancer. They target specific cancer cells, unlike the traditional way, which affects both healthy and cancerous cells in the body. Common drug types include monoclonal antibodies, cancer vaccines, recombinant proteins, and many more. They work by adapting the immune system in the body, blocking tumor growth signals, or directly attacking cancer cells. Cancer biologics often offer care treatment with potentially fewer side effects compared to conventional therapies.

About 1 in 5 people develop cancer in their lifetime, and global incidence is anticipated to increase new cases in the coming years due to population growth and ageing. This market is evolving within a global healthcare environment characterized by a significant and rising burden of cancer, which continues to drive the demand for advanced therapeutic solutions. According to the WHO and its cancer research agency, the International Agency for Research on Cancer, there were about 20 million newly diagnosed cancer cases and approximately 9.7 million cancer-related deaths worldwide in 2022, highlighting the substantial global health challenge posed by the disease. Therefore, governments and public health institutions are listing innovative therapeutic modalities, including biologics, to improve treatment accuracy and improve clinical outcomes as part of broader cancer control strategies.

Cancer Biologics Market- Market Dynamics

Increasing Regulatory Approvals and Clinical Adoption of Biologic Therapies

Governing authorities across major healthcare markets are progressively approving biologic therapies, encouraging their integration into contemporary cancer treatment protocols. As regulatory frameworks facilitate timely access to advanced medicines, healthcare providers are increasingly integrating biologic treatments into cancer care. For instance, according to the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research approved 55 novel drugs in 2023, with oncology remaining one of the most active therapeutic areas for biologic and targeted therapies. Amid these developments, pharmaceutical companies such as Merck & Co. and Bristol Myers Squibb are steadily broadening their biologic oncology pipelines, including immunotherapy medicines such as Keytruda and Opdivo, highlighting increasing medical acceptance of biologic-based cancer therapies. Overall, the growing number of regulatory approvals and expanding clinical use of biologic treatments are fostering progress in oncology care, improving patient access to innovative therapies, and encouraging sustained investment in advanced cancer treatment development.

Cancer Biologics Market- Segmentation Analysis:

The Global Cancer Biologics Market is segmented on the basis of Drug, Application, Mechanism, End User, and Region.

Among the three categories of mechanism, targeted immune modulation is anticipated to play a central role in the market. This is largely due to the increasing adoption of immunotherapy approaches that enhance the body's immune system to recognize and attack cancer cells more effectively. Therapies such as immune checkpoint inhibitors have demonstrated significant clinical benefits across several cancer types, including lung cancer, melanoma, and renal cancer. Government and regulatory data illustrate the growing role of immune-based biologics. A cross-national regulatory study reported that more than 80 clinical indications for immune checkpoint inhibitors have been approved across major markets, covering around 20 different cancer types, with many approvals granted as first-line or combination therapies. In addition, insights published by the Cancer Research Institute (CRI) show that over 120 immunotherapy approvals have been granted globally between 2011 and 2024, with immune checkpoint inhibitors representing the largest share of approved cancer immunotherapies. As a result, targeted immune modulation continues to gain strong clinical acceptance due to its ability to deliver durable responses and improved survival outcomes in several cancers.

On the basis of the drug, monoclonal antibodies are forecasted to register meaningful growth in the cancer biologics market. These drugs are broadly used in oncology because they can precisely target specific proteins on cancer cells, thus enhancing treatment effectiveness while reducing damage to healthy tissues. These biologic drugs are widely applied across several cancer types, including breast cancer, lung cancer, and colorectal cancer, which has supported their growing clinical adoption worldwide. Analysis of FDA biologic approvals in 2024 indicates that 13 monoclonal antibodies received regulatory authorization, including several indicated for oncology, reflecting the continued innovation and regulatory focus on antibody-based biologic medicines. For example, the immunotherapy Keytruda, developed by Merck & Co., generated approximately $29.48 billion in global sales in 2024, making it one of the world's leading oncology biologic medicines.

Cancer Biologics Market- Geographical Insights

Geographically, the cancer biologics market reflects significant regional differences in healthcare infrastructure, research capabilities, and treatment adoption. North America is expected to maintain prominence in the cancer biologics market because, it benefits from advanced healthcare infrastructure, strong government-supported research programs, and a well-established regulatory environment that facilitates the development and approval of innovative biologic cancer therapies. In addition, the occurrence of major biotechnology and pharmaceutical companies, along with extensive clinical research activities, continues to support the regional adoption of biologic-based oncology treatments. Some government data further highlight the strong clinical demand for cancer therapies within the region. According to the American Cancer Society, approximately 20 million new cancer cases and 9.7 million deaths were reported globally in 2022, emphasizing the growing global burden of cancer and the need for advanced treatments such as biologics.

Within North America, the United States represents a major contributor to the regional market due to its large patient population and strong biomedical research ecosystem. According to the Centers for Disease Control and Prevention (CDC) through the United States Cancer Statistics program, 1,851,238 new cancer cases were reported in the United States in 2022, and 613,349 cancer-related deaths occurred in 2023, illustrating the substantial need for advanced cancer treatment solutions. Overall, the combination of a significant cancer burden, supportive government initiatives, advanced healthcare systems, and strong research investments positions the cancer biologics market.

India Cancer Biologics Market- Country Insights

India is gradually emerging as an important market for cancer biologics due to the rising cancer burden, expanding healthcare infrastructure, and increasing focus on biotechnology innovation. According to the Indian Council of Medical Research (ICMR) through the National Cancer Registry Programme (NCRP), India reported approximately 1.46 million new cancer cases in 2022, and the incidence is projected to reach around 1.57 million cases by 2025, highlighting the growing need for advanced treatment options such as biologic therapies. Some government initiatives are also strengthening oncology care in the country. For instance, the Ministry of Health and Family Welfare, Government of India, implements the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), which focuses on improving cancer screening, diagnosis, and treatment infrastructure across states. Together, the growing cancer burden, supportive government healthcare initiatives, and increasing participation of domestic biopharmaceutical companies are collectively strengthening India's role in the cancer biologics landscape. Continued investments in biotechnology research and the expansion of biosimilar production are expected to improve accessibility to advanced cancer therapies and support the gradual development of the country's biologics market.

Cancer Biologics Market- Competitive Landscape:

Cancer Biologics market is highly competitive and innovation driven, categorized by strategic alliances, M&A activity, and robust R&D. The market validates a competitive environment supported by the presence of several global pharmaceutical and biotechnology companies engaged in the development of advanced biologic therapies for oncology. Market participants are prioritizing research and innovation to introduce targeted treatments such as monoclonal antibodies, immune checkpoint inhibitors, and cell-based therapies that aim to improve clinical outcomes for cancer patients. Prominent organizations, including F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc., and other maintain notable positions in the market due to their extensive oncology pipelines and continued focus on biologic innovation. In addition, companies such as AstraZeneca, Pfizer Inc., and many more are actively strengthening their immuno-oncology and biologics research capabilities. Collectively, these companies contribute to a dynamic and innovation-oriented competitive landscape, where continuous product development and collaborative research efforts support the advancement of modern cancer treatment approaches.

Recent Developments:

In February 2026, Innovent Biologics and Eli Lilly partnered to jointly develop oncology and immunology therapies, with Innovent leading early-stage development in China and Lilly managing global commercialization outside Greater China. This collaboration enhances the global cancer biologics pipeline, combining regional expertise and international reach to expand patient access to innovative cancer treatments.

In June 2025, Alvotech and Dr. Reddy's Laboratories partnered to co-develop, manufacture, and commercialize a pembrolizumab biosimilar. By combining Alvotech's R&D and manufacturing expertise with Dr. Reddy's global commercialization network, the collaboration aims to enhance worldwide accessibility to this leading cancer immunotherapy, supporting broader patient access and affordability.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann La Roche Ltd
  • Novartis AG
  • Merck & Co.
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Eli Lilly and Company
  • Sanofi
  • AbbVie Inc.
  • Amgen Inc.
  • BioNTech
  • Genmab
  • Incyte Corporation
  • Roche
  • Bayer
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033

  • Monoclonal antibodies
  • Cell Therapies
  • Recombinant proteins & cytokines
  • Cancer Vaccines
  • Oncolytic viruses

GLOBAL CANCER BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Hematologic cancers
  • Breast Cancer
  • Lung Cancer
  • Colorectal and other solid tumors

GLOBAL CANCER BIOLOGICS MARKET, BY MECHANISM- MARKET ANALYSIS, 2020 - 2033

  • Targeted immune modulation
  • Tumor specific cell based therapies
  • Angiogenesis and growth factor inhibitors
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

GLOBAL CANCER BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Biologics Market Snippet by Drug
    • 2.1.2. Cancer Biologics Market Snippet by Application
    • 2.1.3. Cancer Biologics Market Snippet by Mechanism
    • 2.1.4. Cancer Biologics Market Snippet by End User
    • 2.1.5. Cancer Biologics Market Snippet by Country
    • 2.1.6. Cancer Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Biologics Key Market Trends

  • 3.1. Cancer Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Biologics Market Opportunities
  • 3.4. Cancer Biologics Market Future Trends

4. Cancer Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Cancer Biologics Market Landscape

  • 6.1. Cancer Biologics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Biologics Market - By Drug

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug, 2025 & 2033 (%)
    • 7.1.2. Monoclonal antibodies
    • 7.1.3. Cell Therapies
    • 7.1.4. Recombinant proteins & cytokines
    • 7.1.5. Cancer Vaccines
    • 7.1.6. Oncolytic viruses

8. Cancer Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 8.1.2. Hematologic cancers
    • 8.1.3. Breast Cancer
    • 8.1.4. Lung Cancer
    • 8.1.5. Colorectal and other solid tumors

9. Cancer Biologics Market - By Mechanism

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism, 2025 & 2033 (%)
    • 9.1.2. Targeted immune modulation
    • 9.1.3. Tumor specific cell based therapies
    • 9.1.4. Angiogenesis and growth factor inhibitors
    • 9.1.5. Others

10. Cancer Biologics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Others

11. Cancer Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Cancer Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Cancer Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Cancer Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Cancer Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Cancer Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Cancer Biologics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. F. Hoffmann La Roche Ltd
    • 12.2.2. Novartis AG
    • 12.2.3. Merck & Co.
    • 12.2.4. Bristol Myers Squibb
    • 12.2.5. Johnson & Johnson
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. Sanofi
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Amgen Inc.
    • 12.2.10. BioNTech
    • 12.2.11. Genmab
    • 12.2.12. Incyte Corporation
    • 12.2.13. Roche
    • 12.2.14. Bayer
    • 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us